Addition Therapeutics is a spin-out from Professor Kathleen Collins’ laboratory at the University of California that focuses on an all-RNA, non-viral lipid nanoparticle (LNP) PRINT delivery platform. The technology is designed to produce "PRINTed" therapeutics targeting both chronic and rare diseases. Initial disease-related non-human primate studies are scheduled for 2026 as the company advances its preclinical pipeline. The company is led by CEO Ron Park, M.D., with a leadership team that includes CSO Francine Gregoire, CBO Priya Parameswaran, and other senior executives across operations, IP, and culture. Addition plans to deploy its latest capital to expand operations and scale R&D programs. To date, the company has secured $100 million in external financing, though no revenue or user metrics were disclosed in the article.

Total raised

$100M

Funding rounds

1

Latest round

Equity

Latest activity

Dec 2025